南京健友生化制药股份有限公司 2024 年独立董事述职报告 作为南京健友生化制药股份有限公司（以下简称为"公司"）的独立董事， 本人严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等法律、 法规和《公司章程》的规定，本着维护公司整体利益和全体股东合法权益的原则， 忠实、勤勉地履行职责，独立、客观地发表意见，审慎、理性地行使表决权，积 极推动公司健康、持续发展。现将 2024 年度（以下或称"报告期"）履行职责 的情况报告如下： 一、独立董事的基本情况： 本人金毅，1954 年出生，中国国籍，工商管理硕士，高级经济师，中共党 员。历任招商银行南京分行行长助理、办公室主任、无锡支行行长，招商银行南 京分行副行长、招商银行南京分行行长、招商银行巡视员。2023 年 5 月起担任 公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独 立 性要求，不存在影响独立性的情况。 二、独立董事年度履职情况 （一）董事会和股东大会出席情况 股东大会：2024 年度，公司共召开 2 次股东大会，本人应当出席 2 次，实 际出席了 1 次，会议召开前，本人对提交董事会的会议材料进行认真审核，与 ...

南京健友生化制药股份有限公司 2024 年独立董事述职报告 作为南京健友生化制药股份有限公司（以下简称为"公司"）的独立董事， 本人严格按照《公司法》、《证券法》、《上市公司独立董事管理办法》等法律、 法规和《公司章程》的规定，本着维护公司整体利益和全体股东合法权益的原则， 忠实、勤勉地履行职责，独立、客观地发表意见，审慎、理性地行使表决权，积 极推动公司健康、持续发展。现将 2024 年度（以下或称"报告期"）履行职责 的情况报告如下： 一、独立董事的基本情况： 本人崔国庆先生，1956 年出生，中国国籍，中共党员，无国外永久留居权。 毕业于南京大学，EMBA 硕士。1979 年至 1996 年，任扬州人民银行科长，1996 年至 2016 年，历任招商银行南京分行会计部总经理、行长助理、副行长。2020 年 5 月起担任公司独立董事。 报告期内，本人任职符合《上市公司独立董事管理办法》第六条规定的独立 性要求，不存在影响独立性的情况。 二、独立董事年度履职情况 （一）董事会和股东大会出席情况 股东大会：2024 年度，公司共召开 2 次股东大会，本人应当出席 2 次，实 际出席了 2 次，会议召开前，本人 ...

Financial Performance - The company reported a significant increase in revenue, with a year-on-year growth of 15% in the latest fiscal year[18]. - The company's operating revenue for 2024 was CNY 3,923,585,843.53, a slight decrease of 0.20% compared to CNY 3,931,387,279.72 in 2023[25]. - Net profit attributable to shareholders for 2024 reached CNY 826,144,870.17, a significant increase of 536.09% from a loss of CNY 189,445,790.76 in 2023[25]. - The basic earnings per share for 2024 was CNY 0.51, up 525.00% from a loss of CNY 0.12 in 2023[26]. - The weighted average return on equity increased to 13.47% in 2024, up 16.64 percentage points from -3.17% in 2023[26]. - The company achieved total revenue of 392,358.58 million RMB, a decrease of 0.20% compared to the previous year[84]. - The company's net profit attributable to shareholders increased by 536.09% to 82,614.49 million RMB[84]. - The gross profit margin for the standard heparin raw material was 30.29%, for formulations was 46.04%, and for CDMO and other products was 65.88%, with the overall gross profit margin at 43.28%[89]. Research and Development - The company has invested in new technology development, allocating 10 million yuan for R&D in the upcoming fiscal year[18]. - Research and development (R&D) investment reached RMB 53,239.37 million, representing 13.57% of total revenue, aimed at accelerating the commercialization of the R&D pipeline[36]. - The total R&D investment amounted to CNY 532,393,654.69, representing 13.57% of the operating revenue, with 38.03% of the R&D costs capitalized[99]. - The company has over 500 R&D personnel, including more than 100 with master's or doctoral degrees, enhancing its research capabilities[73]. - The company has a strong pipeline of products under regulatory review, with multiple oncology drugs currently in the documentation review phase in both China and the U.S.[125]. Market Expansion and Strategy - The company has outlined a strategic plan for market expansion, targeting a 20% increase in market share over the next two years[18]. - The company is focusing on expanding its product line, particularly in the biopharmaceutical sector, with new product launches expected in the next quarter[18]. - The company aims to enhance its market access capabilities and commercial team construction in North America, Europe, and South America, achieving significant progress[43]. - The company is expanding its product registration and sales efforts in over 20 countries, successfully entering 9 new markets during the reporting period[42]. - The company aims to provide differentiated CDMO services in the global market, enhancing its reputation and service revenue through compliance with international regulations[62]. Compliance and Governance - The company has received a standard unqualified audit report from Tianye Certified Public Accountants[8]. - The company is committed to maintaining compliance with regulatory standards, including those set by the FDA and other international bodies[18]. - The company’s board of directors and senior management have confirmed the accuracy and completeness of the financial report[6]. - The company has not faced any penalties from securities regulatory agencies in the past three years[179]. - The decision-making procedures and mechanisms regarding dividends are complete and transparent[195]. Dividend Policy - The company plans to distribute a cash dividend of 1.00 yuan per 10 shares (including tax) to all shareholders, pending approval at the 2024 annual general meeting[9]. - The company declared a cash dividend of 16,156.35 million RMB, which represents 19.56% of the net profit attributable to ordinary shareholders in the consolidated financial statements[197]. - The company has a clear and defined dividend policy that aligns with its articles of association and shareholder resolutions[195]. - The company plans to maintain a cash dividend distribution of at least 10% of the distributable profit when conditions are met[192]. - Over the last three accounting years, the cumulative cash dividend amount (including tax) was 50,904.16 million RMB, with an average annual net profit of 57,584.41 million RMB, resulting in a cash dividend ratio of 88.40%[200]. Risk Management - The company has detailed potential risks in its future development plans, emphasizing the importance of risk management[11]. - The fluctuation in raw material prices, particularly for heparin crude products, poses a significant risk to production costs and overall financial performance[161]. - The company has developed a comprehensive response plan to enhance the likelihood of winning bids in national procurement and is actively expanding global sales channels to increase overall sales[163]. - The company has implemented a comprehensive risk management system to maintain product quality and stability, adhering to FDA audit standards[161]. Product Development and Approvals - The company received approvals for 14 generic drugs from the National Medical Products Administration of China and the FDA, expanding its injection product sales pipeline[36]. - The company completed the acquisition of Coherus BioSciences' Yusimry for USD 40 million, becoming the first Chinese company to receive full FDA approval for an adalimumab biosimilar[40]. - The company has established a complete technical system for biopharmaceuticals, with its production bases certified by the FDA, ensuring industry-leading quality control[38]. - The company is actively pursuing regulatory approvals to enhance its competitive edge in the pharmaceutical market[57][58][59]. - The company has received approvals for several products, including fluorouracil injection and voriconazole injection, with approval dates ranging from January to November 2024[126][127]. Human Resources and Management - The company has a total of 1,360 employees, with 736 in the parent company and 624 in major subsidiaries[188]. - The company has established a performance evaluation management system linked to employee responsibilities and skills, promoting various incentive measures[189]. - The company has implemented measures to significantly improve operational efficiency by shortening sales cycles, thereby reducing the impact of exchange rate fluctuations on business operations[163]. - The company is enhancing its talent development initiatives to support sustainable growth and improve operational efficiency[158]. - The total remuneration for all directors, supervisors, and senior management during the reporting period amounted to 4.413 million yuan[177].

Financial Performance - The company's operating revenue for Q1 2025 was ¥885,219,018.08, a decrease of 11.85% compared to ¥1,004,271,789.41 in the same period last year[4] - Net profit attributable to shareholders decreased by 52.19% to ¥84,713,913.06 from ¥177,190,306.66 year-on-year[4] - Basic and diluted earnings per share were both ¥0.05, down 54.55% from ¥0.11 in the previous year[5] - Operating profit for Q1 2025 was ¥92,742,715.49, down 53.3% from ¥198,763,215.13 in Q1 2024[20] - Net profit for Q1 2025 was ¥84,711,072.67, a decline of 52.2% compared to ¥177,186,922.12 in Q1 2024[21] - The company reported a total comprehensive income of ¥84,137,863.79 for Q1 2025, significantly lower than ¥177,164,282.54 in Q1 2024, a drop of 52.5%[21] Assets and Liabilities - Total assets at the end of the reporting period were ¥8,928,306,163.95, down 6.12% from ¥9,509,950,363.94 at the end of the previous year[5] - Total assets decreased to ¥8,928,306,163.95 in Q1 2025 from ¥9,509,950,363.94 in Q1 2024, reflecting a reduction of 6.1%[18] - Total liabilities decreased to ¥2,354,943,269.67 in Q1 2025 from ¥3,021,793,728.13 in Q1 2024, a decline of 22.0%[18] - The company's equity attributable to shareholders increased by 1.31% to ¥6,576,884,929.92 from ¥6,491,670,118.25 at the end of the previous year[5] Cash Flow - The net cash flow from operating activities was ¥164,221,944.29, a decrease of 18.29% compared to ¥200,989,514.81 in the same period last year[4] - In Q1 2025, the net cash flow from operating activities was RMB 164,221,944.29, a decrease of 18.2% compared to RMB 200,989,514.81 in Q1 2024[23] - The company reported a total cash outflow from operating activities of RMB 763,063,144.43 in Q1 2025, a decrease of 3.7% from RMB 792,318,707.32 in Q1 2024[23] - The net cash flow from investment activities was RMB 360,499,633.30 in Q1 2025, recovering from a negative RMB 789,963,439.08 in Q1 2024[24] - The net cash flow from financing activities was negative RMB 612,009,101.81 in Q1 2025, contrasting with a positive RMB 481,803,012.85 in Q1 2024[24] Revenue Segments - The revenue from the heparin raw material segment decreased significantly by 51.61% year-on-year, accounting for 20.06% of total revenue, down from 25.37% in the same period last year[13] - The overall sales revenue of the formulation business grew by 18.30% year-on-year, despite some pressure on domestic formulation revenue due to product re-registration[13] - The international biopharmaceutical segment is expected to see revenue growth driven by the approval of liraglutide in April 2025, following increased investment in the sales team[13] Market Strategy - The company plans to accelerate global market expansion, focusing on regions such as mainland China, Europe, the Middle East, and Canada, to enhance the scale effect of high-quality generic drug registrations[14] - The company aims to expand its high-margin biopharmaceutical product line, establishing a third growth engine for performance[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 16,738[10] - The company has not reported any changes in the participation of major shareholders in margin financing and securities lending activities[12] Research and Development - Research and development expenses for Q1 2025 were ¥69,243,203.24, a decrease of 7.1% from ¥74,903,809.77 in Q1 2024[20] Inventory and Current Assets - The company's total current assets decreased to approximately RMB 6.27 billion from RMB 7.05 billion in the previous period[16] - Inventory levels were reported at approximately RMB 3.40 billion, a decrease from RMB 3.67 billion as of December 31, 2024[16] Government Policies - The company is closely monitoring the impact of the U.S. government's tariff policies on its business, although no significant effects have been observed so far[13] Cash and Cash Equivalents - As of March 31, 2025, the company's cash and cash equivalents amounted to approximately RMB 662.89 million, down from RMB 1,024.38 million as of December 31, 2024[16] - The total cash and cash equivalents at the end of Q1 2025 were RMB 652,795,192.63, down from RMB 786,777,672.92 at the end of Q1 2024[24]

南京健友生化制药股份有限公司 2024 年度会计师事务所履职情况评估报告 南京健友生化制药股份有限公司（以下简称"公司"）聘请公证天业会计师 事务所（特殊普通合伙）（以下简称"公证天业"）作为公司 2024 年度财务及 内部控制审计机构。根据财政部、国资委及证监会颁布的《国有企业、上市公司 选聘会计师事务所管理办法》，公司对公证天业 2024 年审计过程中的履职情况 进行评估。经评估，公司认为公证天业资质等方面合规有效，保持了良好的独立 性，认真履职、勤勉尽责、公允表达意见，具体情况如下： 一、资质条件 公证天业创立于 1982 年，是全国首批经批准具有从事证券、期货相关业务 资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日，转制为特殊 普通合伙企业。执行事务合伙人/首席合伙人：张彩斌，注册地址：无锡市太湖 新城嘉业财富中心 5-1001 室。 公证天业 2024 年度经审计的收入总额 30,857.26 万元，其中审计业务收入 26,545.80 万元，证券业务收入 16,251.64 万元。2024 年度上市公司年报审计客 户家数 81 家，审计收费总额 8,151.63 万元，上 ...

证券代码：603707 证券简称：健友股份 公告编号：2025-028 南京健友生化制药股份有限公司 关于以集中竞价方式回购股份的预案 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 回购股份金额：本次回购股份的资金总额不低于人民币 2,000 万元（含）且不 超过人民币 4,000 万元（含） ● 回购股份资金来源：公司自有资金或招商银行股份有限公司南京分行提供的专 项贷款 ● 回购股份期限：自公司股东大会审议通过本次回购股份方案之日起 12 个月内 ● 相关股东是否存在减持计划：截至董事会通过本次回购方案决议日，公司控股 股东、董事、监事、高级管理人员不存在未来 3 个月、未来 6 个月减持本公司股 份的计划。 ● 相关风险提示： （一）回购期限内，若公司股票价格持续超出回购方案披露的价格上限，存在回 购方案无法实施的风险； （三）回购股份所需资金未能及时到位，导致回购方案无法按计划实施的风险； （四）因公司生产经营、财务状况、外部客观情况发生重大变化等原因，则存在 根据相关规则变更或终止本次回购方 ...

| 证券代码：603707 | 证券简称：健友股份 | 公告编号：2025-027 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 重要内容提示： 南京健友生化制药股份有限公司（以下简称"公司"）于 2025 年 4 月 28 日召开第五届董事会第十二次会议和第五届监事会第九次会议，审议通过了《关 于转回存货跌价准备的议案》。现将具体情况公告如下： 一、本次拟计提或转回存货跌价准备概况 为客观反映公司财务状况和资产价值，根据《企业会计准则》及公司会计政 策等相关规定，公司对相关资产进行了减值测试，根据测试结果，基于谨慎性原 则，公司拟计提或转回部分存货跌价准备。 二、本次拟计提或转回存货跌价准备的具体情况 单位：万元 | 项目 | 本期计提和转回情况 （转回为负数） | | --- | --- | | 原材料 | -1,080.66 | | 在产品 | 208.73 | | 库存商品 | -10,756.88 | | 发出商品 | | | 委托加工物资 | | | 合计 | -11,628.81 | 三、本次计提或转回存货跌 ...

重要内容提示： 本次会计政策变更是根据中华人民共和国财政部（以下简称"财政部"） 2024年12月6日发布的《企业会计准则解释第18号》进行的相应变更，无需提交 公司董事会和股东大会审议，对公司的财务状况、经营成果和现金流量不会产 生重大影响。 一、本次会计政策变更概述 南京健友生化制药股份有限公司（以下简称"公司"）根据财政部发布的《企 业会计准则解释第18号》的相关规定和要求，结合公司实际情况，对相关会计 政策进行了相应变更。根据《上海证券交易所股票上市规则》等相关规定，本 次会计政策变更无需提交公司董事会审计委员会、董事会、监事会和股东大会审 议。 二、本次会计政策变更具体情况 | 股票代码：603707 | 股票简称：健友股份 | 公告编号：2025-018 | | --- | --- | --- | | 债券代码：113579 | 债券简称：健友转债 | | 南京健友生化制药股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 本次会计政策变更前，公司执行财政部发布的《企业会计准则—基 ...

南京健友生化制药股份有限公司 审计委员会 2024 年度履职情况报告 根据《公司法》、《证券法》、《上市公司治理准则》、《企业内部控制基本规范》、 《上海证券交易所股票上市规则》、《上海证券交易所上市公司自律监管指引第 1 号——规范运作》等法律法规的有关规定，南京健友生化制药股份有限公司（以 下简称"健友股份"或"公司"）审计委员会本着勤勉尽责的原则，积极开展工 作，认真履行职责，现将审计委员会 2024 年度履职情况报告如下： | 时间 | 届次 | 会议审议内容 | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 年 | 月 | 日 | 年第一次 | 1、《2023 | 年度财务决算报告》的议案 | 2024 | 4 | 24 | 2024 | 2、《2023 | 年度审计委员会履职情况报告》的议案 | | 3、《董事会审计委员会对会计师事务所 | 年度履行监督职责 | 2023 | 情况的报告》的议案 | | | | | | | | | | 4、《2023 | 年 ...

南京健友生化制药股份有限公司董事会审计委员会 对会计师事务所 2024 年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理 准则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所上 市公司自律监管指引第 1 号——规范运作》和南京健友生化制药股份有限公司 (以下简称"公司")的《公司章程》《审计委员会工作细则》等规定和要求，董 事会审计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委 员会对会计师事务所 2024 年度履职情况评估及履行监督职责的情况汇报如下： 一、2024 年年审会计师事务所基本情况 （一）会计师事务所基本情况 （1） 会计师事务所名称：公证天业会计师事务所（特殊普通合伙） （2） 成立日期：公证天业创立于 1982 年，是全国首批经批准具有从事证 券、期货相关业务资格及金融业务审计资格的会计师事务所之一。2013 年 9 月 18 日，转制为特殊普通合伙企业。 （3） 组织形式：特殊普通合伙企业 （4） 注册地址：无锡市太湖新城嘉业财富中心 5-1001 室 （5） 执行事务合伙人/首席合伙人：张彩斌 二、聘任会计师事 ...